David Nierengarten
Stock Analyst at Wedbush
(4.42)
# 327
Out of 5,149 analysts
214
Total ratings
53.98%
Success rate
18.55%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Maintains: Outperform | $90 → $95 | $73.14 | +29.90% | 4 | Mar 3, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 → $65 | $27.66 | +135.00% | 4 | Feb 25, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $50 → $53 | $44.59 | +18.86% | 6 | Feb 25, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $13.32 | +50.15% | 10 | Feb 24, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Underperform | $110 | $115.02 | -4.36% | 1 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Outperform | $110 → $88 | $63.33 | +38.95% | 5 | Feb 17, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $4.35 | +153.16% | 12 | Feb 10, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $5.28 | +108.33% | 5 | Jan 30, 2026 | |
| COGT Cogent Biosciences | Reiterates: Outperform | $55 | $36.92 | +48.97% | 4 | Jan 21, 2026 | |
| IMNM Immunome | Reiterates: Outperform | $31 | $22.13 | +40.08% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $18 | $12.98 | +38.67% | 9 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $742.51 | +34.68% | 24 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $17.50 | +71.43% | 3 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $10.00 | +150.00% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $13.96 | -49.86% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.38 | +407.25% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $101.22 | +13.61% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4 | $4.38 | -8.68% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $12.10 | +114.88% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $6.84 | +221.64% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $14.55 | -45.00% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $20.20 | -0.99% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $58.20 | -31.27% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $44.73 | +5.07% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $33.70 | +18.69% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $40.92 | +9.97% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.05 | +852.38% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $5.43 | +231.49% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.29 | +179.72% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.33 | +21,359.23% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $9.22 | +550.76% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.20 | +131.71% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $21.78 | +244.35% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.15 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.11 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.47 | - | 3 | Nov 20, 2017 |
Apogee Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $73.14
Upside: +29.90%
Beam Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $27.66
Upside: +135.00%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Outperform
Price Target: $50 → $53
Current: $44.59
Upside: +18.86%
ORIC Pharmaceuticals
Feb 24, 2026
Reiterates: Outperform
Price Target: $20
Current: $13.32
Upside: +50.15%
ABIVAX Société Anonyme
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $115.02
Upside: -4.36%
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $63.33
Upside: +38.95%
Nuvation Bio
Feb 10, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.35
Upside: +153.16%
Perspective Therapeutics
Jan 30, 2026
Reiterates: Outperform
Price Target: $11
Current: $5.28
Upside: +108.33%
Cogent Biosciences
Jan 21, 2026
Reiterates: Outperform
Price Target: $55
Current: $36.92
Upside: +48.97%
Immunome
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $22.13
Upside: +40.08%
Jan 15, 2026
Reiterates: Neutral
Price Target: $18
Current: $12.98
Upside: +38.67%
Jan 14, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $742.51
Upside: +34.68%
Jan 13, 2026
Reiterates: Outperform
Price Target: $30
Current: $17.50
Upside: +71.43%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $10.00
Upside: +150.00%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $13.96
Upside: -49.86%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.38
Upside: +407.25%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $101.22
Upside: +13.61%
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $4.38
Upside: -8.68%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $12.10
Upside: +114.88%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $6.84
Upside: +221.64%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $14.55
Upside: -45.00%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $20.20
Upside: -0.99%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $58.20
Upside: -31.27%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $44.73
Upside: +5.07%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $33.70
Upside: +18.69%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $40.92
Upside: +9.97%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.05
Upside: +852.38%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $5.43
Upside: +231.49%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.29
Upside: +179.72%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.33
Upside: +21,359.23%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $9.22
Upside: +550.76%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.20
Upside: +131.71%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $21.78
Upside: +244.35%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.11
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.47
Upside: -